Core Viewpoint - RiboBio-B (06938) has received implied approval from the National Medical Products Administration of China for the Phase II clinical trial of its self-developed RBD5044 injection, which targets APOC3 and addresses complications related to hypertriglyceridemia [1] Group 1 - RBD5044 is a siRNA drug that specifically targets APOC3, a protein synthesized almost exclusively in the liver [1] - APOC3 plays a critical role in lipid metabolism, making RBD5044 a potential treatment option for managing dyslipidemia [1] - The drug aims to address complications associated with hypertriglyceridemia, providing a new therapeutic choice in lipid management [1]

Core Viewpoint - Reborn Bio-B (06938.HK) has received implied approval from the National Medical Products Administration of China for the Phase II clinical trial of its self-developed RBD5044 injection, a targeted siRNA drug aimed at APOC3 [1] Group 1: Product Development - RBD5044 is designed to target APOC3, a protein primarily synthesized in the liver that plays a crucial role in lipid metabolism [1] - The drug addresses complications associated with hypertriglyceridemia, providing a treatment option for managing dyslipidemia [1]

Core Viewpoint - The company has submitted a clinical trial application for its self-developed siRNA drug FB7013, targeting the MASP-2 protein, for the treatment of primary IgA nephropathy, marking it as the first-in-class drug in this category [1][2]. Drug Registration Clinical Trial Application - Product Name: FB7013 Injection - Application Matter: Domestic production drug registration clinical trial - Indication: Intended for the treatment of primary IgA nephropathy - Approval Conclusion: The application has been accepted according to the Administrative Licensing Law of the People's Republic of China [1]. Drug Mechanism - FB7013 is the first siRNA drug globally to target the MASP-2 protein, with potential for first-in-class status. It aims to inhibit MASP-2 activity to block the abnormal activation of the lectin pathway, thereby reducing complement-mediated kidney tissue damage. Future applications may extend to diseases related to complement activation, such as membranous nephropathy and diabetic nephropathy [2]. Preclinical Research Data - In healthy crab-eating macaques, FB7013 demonstrated strong and lasting inhibition of the target protein, achieving over 95% knockdown of serum MASP-2 protein after a single subcutaneous injection, with over 90% knockdown maintained for 105 days. This suggests potential for administration every 3-6 months in clinical settings, enhancing patient compliance. In IgA nephropathy models, FB7013 showed significant efficacy and good safety profile, with dose-dependent reductions in urinary protein levels and increases in glomerular filtration rate. High-dose treatment for 8 weeks resulted in a 36% reduction in mesangial cell numbers and a 43% reduction in IgA deposition. No significant off-target risks were identified [3]. Potential Market Outlook - IgA nephropathy is one of the most common primary glomerular diseases globally, characterized by abnormal deposition of IgA immune complexes in the glomeruli, leading to chronic kidney failure. According to Frost & Sullivan, the number of IgA nephropathy patients increased from 8.8 million in 2015 to 9.3 million in 2020, and is expected to reach 10.2 million by 2030. The global market for IgA nephropathy treatment drugs is projected to grow from $567 million in 2020 to $1.196 billion by 2025, with a compound annual growth rate of 16.1%, indicating significant market potential [5].

Core Viewpoint - Rebio Biotech, established in 2007, is attempting to go public in Hong Kong after previously withdrawing its application for the Sci-Tech Innovation Board in 2020. Despite being recognized as a leader in the small nucleic acid drug sector, the company has yet to commercialize any self-developed drugs, relying heavily on financing and technology licensing for revenue [1][3]. Financial Performance - Rebio Biotech reported a revenue of RMB 44,000 in 2023, which is projected to increase to RMB 1.43 billion in 2024. However, net losses for the same periods were RMB 4.37 billion and RMB 2.81 billion, respectively, leading to a cumulative loss exceeding RMB 7 billion over two years [4][5]. - The company's total assets fluctuated from approximately RMB 7.16 billion in 2023 to RMB 10 billion in 2025, while total liabilities increased from RMB 6 billion to RMB 9.42 billion during the same period [5][6]. Funding and Financing - From 2015 to 2025, Rebio Biotech raised a total of RMB 1.829 billion from various investors, including Hillhouse Capital and CICC Capital. However, the company's valuation has been volatile, dropping from RMB 48.7 billion in 2024 to RMB 35.8 billion in 2025 [8][9]. - The company has been utilizing a combination of financing and business development (BD) partnerships to maintain operations, with significant contributions from collaborations, such as a deal with Qilu Pharmaceutical worth over RMB 700 million [9][11]. Research and Development - Rebio Biotech has developed a large pipeline of siRNA drugs, with six self-developed drug assets in clinical trials targeting various diseases. However, the company's resource allocation for core product development has been low, with only 19.1% to 25.9% of total R&D spending directed towards core products from 2023 to 2025 [12][14]. - The company has not established its own production facilities, relying on outsourcing for clinical sample production, which poses a challenge in the competitive landscape [16]. Market Position and Competition - The global small nucleic acid drug market is projected to grow from USD 2.7 billion in 2019 to USD 46 billion by 2033, with Rebio Biotech's core product, RBD4059, being the first siRNA drug for thrombotic diseases in clinical development. However, it faces competition from other companies that have advanced further in clinical trials [13][14].